167 related articles for article (PubMed ID: 18065960)
21. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
22. [Female patient with Muir-Torre syndrome].
Negraszus N; Jöhrens K; Bertelmann E
Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
[TBL] [Abstract][Full Text] [Related]
23. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
24. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
25. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome.
Entius MM; Keller JJ; Drillenburg P; Kuypers KC; Giardiello FM; Offerhaus GJ
Clin Cancer Res; 2000 May; 6(5):1784-9. PubMed ID: 10815898
[TBL] [Abstract][Full Text] [Related]
26. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
[TBL] [Abstract][Full Text] [Related]
27. Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome.
Georgeson P; Walsh MD; Clendenning M; Daneshvar S; Pope BJ; Mahmood K; Joo JE; Jayasekara H; Jenkins MA; Winship IM; Buchanan DD
Mol Genet Genomic Med; 2019 Jul; 7(7):e00781. PubMed ID: 31162827
[TBL] [Abstract][Full Text] [Related]
28. Muir-Torre Syndrome / Turcot Syndrome overlap? A patient with sebaceous carcinoma, colon cancer, and a malignant astrocytoma.
Kleinerman R; Marino J; Loucas E
Dermatol Online J; 2012 May; 18(5):3. PubMed ID: 22630573
[TBL] [Abstract][Full Text] [Related]
29. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
[TBL] [Abstract][Full Text] [Related]
30. [The tip of the iceberg: multiple cutaneous sebaceous tumor in colon cancer. Muir-Torre syndrome--case report].
Herr G; Szenes M; Hohl G; Vinkler ME; Tüske G; Horváth J; Nagy G; Tihanyi M; Széll M; Nagy N; Gasztonyi B
Orv Hetil; 2015 Jun; 156(24):979-84. PubMed ID: 26051134
[TBL] [Abstract][Full Text] [Related]
31. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions.
Marazza G; Masouyé I; Taylor S; Prins C; Gaudin T; Saurat JH; French LE
Arch Dermatol; 2006 Aug; 142(8):1039-42. PubMed ID: 16924054
[TBL] [Abstract][Full Text] [Related]
32. Clinico-pathological predictors of mismatch repair deficiency in sebaceous neoplasia: A large case series from a single Australian private pathology service.
Walsh MD; Jayasekara H; Huang A; Winship IM; Buchanan DD
Australas J Dermatol; 2019 May; 60(2):126-133. PubMed ID: 30506759
[TBL] [Abstract][Full Text] [Related]
33. More than just skin deep!: a report on a family with Muir-Torre syndrome.
Jairam N; Shivaram HV; Murthy RA; Yadav N; Sathish N; Kumar V A; Payal K; Pandey V
Int J Colorectal Dis; 2007 Aug; 22(8):987-9. PubMed ID: 16575605
[No Abstract] [Full Text] [Related]
34. A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome.
Mangold E; Pagenstecher C; Leister M; Mathiak M; Rütten A; Friedl W; Propping P; Ruzicka T; Kruse R
J Med Genet; 2004 Jul; 41(7):567-72. PubMed ID: 15235030
[No Abstract] [Full Text] [Related]
35. Muir-Torre syndrome.
Cohen PR; Kohn SR; Davis DA; Kurzrock R
Dermatol Clin; 1995 Jan; 13(1):79-89. PubMed ID: 7712655
[TBL] [Abstract][Full Text] [Related]
36. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
[TBL] [Abstract][Full Text] [Related]
37. Loss of fragile histidine triad (FHIT) expression and microsatellite instability in periocular sebaceous gland carcinoma in patients with Muir-Torre syndrome.
Holbach LM; von Moller A; Decker C; Jünemann AG; Rummelt-Hofmann C; Ballhausen WG
Am J Ophthalmol; 2002 Jul; 134(1):147-8. PubMed ID: 12095833
[TBL] [Abstract][Full Text] [Related]
38. Multiple benign adnexal tumours: Anything but benign.
McCarthy RL; Thomas CL; Isaacs F
Australas J Dermatol; 2019 Aug; 60(3):234-236. PubMed ID: 30671930
[TBL] [Abstract][Full Text] [Related]
39. Loss of mismatch repair proteins in sebaceous gland tumors.
Popnikolov NK; Gatalica Z; Colome-Grimmer MI; Sánchez RL
J Cutan Pathol; 2003 Mar; 30(3):178-84. PubMed ID: 12641777
[TBL] [Abstract][Full Text] [Related]
40. An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation.
Arnold A; Payne S; Fisher S; Fricker D; Soloway J; White SM; Novelli M; MacDonald K; Mackay J; Groves R; Canham N
Fam Cancer; 2007; 6(3):317-21. PubMed ID: 17323113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]